PRESS RELEASE

UK PRIME MINISTER, DAVID CAMERON, ENDORSES PROTEOME SCIENCES' IN KEY NOTE SPEECH AT G8 DEMENTIA SUMMIT

20 December 2013, Cobham, UK - Proteome Sciences plc ('Proteome Sciences') is pleased to report that during his key note address at The G8 Dementia Summit held in London on Wednesday 11th December, UK Prime Minister, David Cameron identified Proteome Sciences as one of the companies developing new tests in Alzheimer's:

"There is hope. I see it in the extraordinary work of UK life sciences companies like Proteome Sciences, working with others to develop new tests for Alzheimer's Disease".

Christopher Pearce, CEO of Proteome Sciences, who attended the Pre G8 Dementia Meeting with global leaders in the field on 10th December 2013, said:

> "We are absolutely delighted that David Cameron drew attention to the ground-breaking work Proteome Sciences is undertaking in discovering and validating blood biomarkers to be used for early stage diagnosis of Alzheimer's disease (AD). The research is at an advanced stage following our disclosure of excellent results in the summer showing positive predictive accuracy of 94% in AD and 88% in mild cognitive impairment (MCI) and brings the prospects of a blood test significantly closer.
>
> We are also strongly encouraged by the news from our collaboration with researchers at Kings College, London that they have made a significant step in developing a test which could allow doctors to detect AD at an early stage before any noticeable warning signs. Out of tens of thousands of proteins in blood, the group have identified 10 on results from over 1000 individuals that they believe could be used to identify Alzheimer's and we await further results with great interest."
>
> Professor Simon Lovestone at the Institute of Psychiatry, Kings College, London said:
>
> "We are nervous about claiming too many breakthroughs but I think we are seeing in this study more promising data than I have seen before."

Proteome Sciences has established a comprehensive range of biomarker assays and services in AD for the pharmaceutical industry as it switches programmes increasingly to tackle tau tangles in combination with beta amyloid plaques for the next generation of drugs and patient management. Our biomarkers can be used for increasing the speed and reducing the cost of clinical trials, for patient stratification, drug development and testing and monitoring patient response. The G8 Summit pulled together health ministers from around the world to develop co-ordinated global action on dementia calling for innovation and working collectively in partnership with the ambition to identify a cure or disease modifying therapy for dementia by 2025.

Christopher Pearce concluded:

> "At Proteome Sciences we firmly believe the use of protein biomarkers and related proteomics technologies has a vital role to play in finding the means to successfully diagnose early and treat what is one of the most distressing and debilitating diseases of our time and that our contribution will be pivotal in that process ".

.

- Ends -

For further information please contact:

Proteome Sciences plc
www.proteomics.com
Christopher Pearce, Chief Executive Officer
Dr. Ian Pike, Chief Operating Officer
James Malthouse, Finance Director Tel: +44 (0)1932 865065

Public Relations
IKON Associates Tel : +44 (0)1483 271291
Adrian Shaw Mob : +44 (0)797 9900733

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.
Visit: http://www.proteomics.com